Szela Mary T

CEO Mary T Szela buys 39,682 shares at $2.59; stock down 34.8% in 30 days, -61.9% from 52-week high.

CEO Mary T Szela purchased 39,682 shares at $2.59 on 2026-05-15, increasing her holding to 1,065,215 shares. The stock has declined 34.8% over the past 30 days and trades 61.9% below its 52-week high of $7.95. At TLSI specifically, Szela's 5 prior buy trades showed mixed near-term results: 3 of 5 achieved positive 90-day returns. Her cross-ticker track record shows 9 prior buys with an average 90-day return of -9.6% and a 90d win rate of 33.33%. The company reported latest-quarter revenue of $8,899,000 and net income of $1,539,000, though it was unprofitable over its most recent full fiscal year. Two other insiders also bought within the past 14 days, creating a cluster buy pattern during a period of significant stock price weakness.

CEO Szela buys 30,487 shares at $4.10; stock down 33.5% from 52-week high, as company unprofitable with -$10.8M net income.

CEO Mary T Szela purchased 30,487 shares at $4.10, increasing her holdings to 773,289 shares, concurrent with a multi-insider buying cluster (4 other insiders bought within 14 days). The purchase occurs as TLSI stock has declined 33.5% from its 52-week high and dropped 20.7% over the past 90 days, while the company reported negative net income of -$10.8M on latest quarterly revenue of $11.6M despite 59.0% annual revenue growth. Her same-ticker trade history shows mixed predictive value: three of five prior TLSI purchases achieved positive 90-day returns, though the most recent prior buy on 2025-01-30 followed a pattern where gains materialized at the 30-day mark but reversed by 90 days. The synchronized multi-insider accumulation during a drawdown, coupled with the company's unprofitability, warrants examination of whether this reflects conviction in the business turnaround or a response to valuation dislocations in a loss-making firm.

CEO Mary T Szela buys 10,040 shares at $5.15 blended; stock down 50.2% from 52-week high; her prior buys at TLSI showed 0 wins at 90 days.

Mary T Szela, CEO and President of TriSalus Life Sciences, purchased 10,040 shares across 2 transactions (5,030 shares at $5.03 on 2025-01-29 and 5,010 shares at $5.28 on 2025-01-30) for $51,753.70 combined, at a blended price of $5.15. The current price is $5.11, placing the stock at -50.2% from its 52-week high of $10.25. Within the prior 14 days, 2 other insiders also bought stock, marking a cluster pattern. However, Szela's own track record at TLSI is concerning: her 5 prior trades at this ticker include 3 measurable 90-day outcomes from prior buys (2024-09-12 through 2024-09-13), all of which declined (returns of -18.5%, -15.2%, and -12.2%), with a 90-day win rate of 0.00% on those purchases. The company reported net income of $-2,399,000.00 against quarterly revenue of $7,349,000.00, indicating ongoing unprofitability despite 49.3% annual revenue growth. Szela's cross-ticker track record shows a 0.00% win rate across 6 prior buys with an average 90-day return of -20.1%, suggesting a pattern of poorly-timed purchases that warrants investor scrutiny of the fundamentals and timing behind this acquisition.

CEO Mary T Szela purchases 9,542 shares at blended $5.27 at TLSI; stock now trading -52.3% from 52-week high at $4.89.

Mary T Szela, CEO and President, executed 2 separate purchases totaling 9,542 shares for $50,302.84 between January 27–28, 2025, at prices ($5.42 and $5.12) well above the current price of $4.89. Her position grew 2.2% to 434,219 shares post-transaction. This filing occurs in a cluster environment where 2 other insiders also bought within the past 14 days, suggesting synchronized insider accumulation. However, her prior buy history at this ticker is concerning: across 4 prior purchases at TLSI between September and January, all four generated negative 90-day returns (ranging from -15.9% to -26.0%), with a 0% success rate at the 90-day mark. The company is unprofitable (net income -$2.4M in the latest quarter) despite strong annual revenue growth of +49.3%, and her cross-ticker track record shows 5 prior buys with an average 90-day return of -20.1% and a 0% win rate. The insider is purchasing at prices significantly above current market levels, and the stock has declined 1.4% over 30 days despite a +23.2% recovery over 90 days.

CEO Mary T Szela purchases 14,815 shares across 3 transactions (avg $5.09) as TLSI stock trades -55.9% from 52-week high.

Mary T Szela, CEO and President of TriSalus Life Sciences, made 3 separate purchases totaling 14,815 shares for $75,358.85 at a blended average price of $5.09 between September 12–13, 2024. This raised her holdings from 369,862 shares to 384,677 shares (+4.0%). The timing coincides with significant stock weakness: the current price of $4.52 sits -55.9% below the 52-week high of $10.25 and down -22.8% over the prior 30 days. The company faces fundamental headwinds—it reported net income of $-4,332,000.00 against quarterly revenue of $7,364,000.00 and has not achieved profitability on a full-year basis, despite posting annual revenue growth of +49.3%. The CEO's discretionary purchase of a material number of shares during a steep drawdown warrants attention to whether she views the decline as an opportunity or whether near-term cash burn concerns should constrain investor confidence.

TLSI CEO Mary T Szela purchased 5,000 shares at $4.97; stock now $5.14, down 49.8% from 52-week high.

Mary T Szela, CEO and President, acquired 5,000 shares of TriSalus Life Sciences at $4.97 on 2024-09-10, bringing her post-transaction holdings to 369,862 shares. The company is unprofitable (net income of $-4,332,000.00 in the latest quarter), though it reported annual revenue growth of +49.3%. The stock has declined 49.8% from its 52-week high of $10.25 and is down 10.6% over the past 30 days. The CEO's purchase represents a modest addition (+1.4% vs pre-transaction holdings) at a price near current levels ($5.14), with limited context from prior trading patterns at this ticker (only one prior measurable trade outcome not yet available).